Climb Bio, Inc. (CLYM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Climb Bio announced Q1 2026 financial results on May 7, 2026, though the specific financial metrics, revenue figures, and operational performance details are not disclosed in the 8-K itself and are contained only in the referenced press release (Exhibit 99.1).
The company is classified as an emerging growth company, which allows it to take advantage of scaled disclosure requirements and extended transition periods for new accounting standards, reducing near-term compliance burdens.
The 8-K filing is minimal in substantive content, serving primarily as a procedural vehicle to announce earnings results rather than disclosing material agreements, strategic developments, or significant corporate events that would typically drive stock movement.
As a biotech company trading on Nasdaq under ticker CLYM, investor assessment of this filing will depend entirely on the earnings details contained in the press release attachment, which is explicitly noted as 'furnished' rather than 'filed' and carries reduced liability implications.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-05

Climb Bio is hosting a virtual investor event on May 5, 2026 to discuss budoprutug, an anti-CD19 monoclonal antibody in clinical development for three indications: primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
The company is a Delaware-incorporated emerging growth company trading on Nasdaq under ticker CLYM, indicating it is relatively early-stage with access to scaled regulatory accommodations.
This is a routine Regulation FD disclosure filing for an investor event with accompanying press release and presentation materials, representing standard investor relations activity with no material corporate events or financial disclosures.

Filed: 2026-04-28

Climb Bio is raising approximately $110 million through a private placement of 9.48 million common shares at $9.50 per share plus 2.1 million pre-funded warrants, providing substantial capital for operations and development.
RA Capital Management is a significant investor with special terms including a higher beneficial ownership threshold of 33% (vs. 4.99-9.99% for other investors) and voting agreement restrictions, indicating strategic partnership and potential board influence.
The company must file a resale registration statement within 45 days post-closing and keep it effective, with potential liquidated damages for missing deadlines, creating near-term regulatory and operational obligations.
Pre-funded warrants with $0.0001 exercise price are immediately exercisable, creating potential for significant dilution as investors can rapidly convert positions into common shares.

Filed: 2026-04-03

Climb Bio, Inc. has announced the departure of its Senior Vice President of Finance, Cindy Driscoll, effective April 30, 2026.
The company's Chief Financial Officer, Susan Altschuller, Ph.D., MBA, will take on the additional role of principal accounting officer, effective the same date.
Dr. Altschuller has significant experience as a CFO in the biotechnology industry, having previously held similar roles at Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen.

Filed: 2026-03-05

Climb Bio, Inc. reported its financial results for the quarter and year ended December 31, 2025.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
The press release containing the financial results is attached as an exhibit to the filing.

Filed: 2026-01-08

Climb Bio has made progress on several key pipeline programs, including dosing the first patient in a Phase 2 trial for primary membranous nephropathy, receiving clearance to initiate a Phase 1b trial in China for systemic lupus erythematosus, and completing dosing in early-stage trials for subcutaneous budoprutug and CLYM116.
The company expects to report initial data from multiple clinical trials in 2026, including the Phase 1 subcutaneous budoprutug trial, the China SLE trial, the Phase 2 primary membranous nephropathy trial, and the Phase 1b/2a immune thrombocytopenia and global SLE trials.
Climb Bio estimates its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2028, providing a solid financial runway to advance its pipeline.

Filed: 2025-12-31

Climb Bio has filed a lawsuit against Alumis Inc. and its subsidiary Acelyrin, Inc. regarding a dispute over an asset purchase agreement related to Climb Bio's drug candidate budoprutug.
The dispute centers around whether budoprutug is considered a 'Product' under the asset purchase agreement, and whether Climb Bio owes a milestone payment to Alumis.
The outcome of this legal dispute could have implications for Climb Bio's development and commercialization plans for budoprutug, a clinical-stage anti-CD19 monoclonal antibody for B-cell mediated diseases.

Other reports for Climb Bio, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.